Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 8/20 | 1.00 |
| ▸ | NQO2 | P16083 | 5/20 | 1.00 |
| ▸ | CYP1A1 | P04798 | 5/20 | 0.74 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.74 |
| ▸ | ESR1 | P03372 | 4/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.74 |
| ▸ | ABL1 | P00519 | 2/20 | 0.74 |
| ▸ | TTR | P02766 | 2/20 | 0.74 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.74 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.74 |
| ▸ | BCR | P11274 | 2/20 | 0.74 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.74 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.74 |
| ▸ | TUBB | P07437 | 2/20 | 0.74 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.74 |
| ▸ | AHR | P35869 | 2/20 | 0.74 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.74 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.74 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.74 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3359255 | 1.00 | CYP19A1 (1.00) | CYP19A1NQO2CYP1A1CYP1B1ESR1 | |
| SCHEMBL10277154 | 1.00 | CYP19A1 (1.00) | CYP19A1NQO2CYP1A1CYP1B1ESR1 | |
| SCHEMBL2588797 | 0.85 | CYP19A1 (0.74) | CYP19A1NQO2CYP1A1CYP1B1ESR1 | |
| 8Z-3,4',5-Trimethoxystilbene SCHEMBL1006207 | 0.85 | CYP1A1 (1.00) | CYP19A1NQO2CYP1A1CYP1B1ESR1 | |
| Trismethoxyresveratrol SCHEMBL918740 | 0.85 | CYP1A1 (1.00) | CYP19A1NQO2CYP1A1CYP1B1ESR1 | |
| Trismethoxyresveratrol SCHEMBL918739 | 0.85 | CYP1A1 (1.00) | CYP19A1NQO2CYP1A1CYP1B1ESR1 | |
| SCHEMBL2588799 | 0.85 | CYP19A1 (0.74) | CYP19A1NQO2CYP1A1CYP1B1ESR1 | |
| SCHEMBL3395077 | 0.84 | PTGS2 (0.86) | CYP19A1NQO2CYP1A1CYP1B1ESR1 | |
| SCHEMBL3365675 | 0.83 | CYP19A1 (1.00) | CYP19A1NQO2CYP1A1CYP1B1CYP1A2 | |
| SCHEMBL3365670 | 0.83 | CYP19A1 (1.00) | CYP19A1NQO2CYP1A1CYP1B1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426369-B2 | Prevention and treatment of colon cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-04-23 | — | — | US | claimed |
| US-8426369-B2 | Prevention and treatment of colon cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-04-23 | — | — | US | disclosed |
| US-20120178704-A1 | PREVENTION AND TREATMENT OF COLON CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2012-07-12 | — | — | US | disclosed |
| CN-101560223-B | Phosphoryl amino acid stilbene derivative, preparing method and application thereof | GRADUATE SCHOOL AT SHENZHEN, TSINGHUA UNIVERSITY (CN) | 2011-12-07 | — | — | CN | disclosed |
| WO-2010046926-A2 | NOVEL STILBENE ANALOGS | APTUIT LAURUS PVT LTD (IN) | 2010-04-29 | — | — | WO | disclosed |
| CN-101560223-A | Phosphoryl amino acid stilbene derivative, preparing method and application thereof | UNIV TSINGHUA GRADUATE SCHOOL (CN) | 2009-10-21 | — | — | CN | disclosed |
| US-6066757-A | MAY BE INCORPORATED INTO PHOTOCONDUCTING LAYER OF ELECTROPHOTOGRAPHIC PHOTOCONDUCTOR AS CHARGE TRANSPORTING MATERIAL | RICOH COMPANY, LTD. (JP) | 2000-05-23 | — | — | US | disclosed |
| US-5641598-A | HAVING HIGH RESISTANCE TO THERMAL AND MECHANICAL SHOCK | RICOH COMPANY, LTD. (JP) | 1997-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178704-A1 | PREVENTION AND TREATMENT OF COLON CANCER | APC, SI, NFKBIA | CYP19A1 614/4885NQO2 1440/4885CYP1A1 1123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.